Cytokinetics (NASDAQ:CYTK) Insider Sells $794,877.72 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) insider Jeffrey Hessekiel sold 15,106 shares of Cytokinetics stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $52.62, for a total transaction of $794,877.72. Following the transaction, the insider directly owned 92,837 shares in the company, valued at approximately $4,885,082.94. This represents a 13.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Cytokinetics Stock Down 1.4%

CYTK opened at $50.76 on Friday. The stock has a market cap of $7.07 billion, a P/E ratio of -8.40 and a beta of 0.45. Cytokinetics, Incorporated has a 12 month low of $50.32 and a 12 month high of $88.31. The company has a fifty day simple moving average of $61.89 and a 200 day simple moving average of $69.46.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) EPS for the quarter, topping analysts’ consensus estimates of ($1.43) by $0.06. The company had revenue of $47.56 million for the quarter, compared to analyst estimates of $41.88 million. During the same quarter in the previous year, the business earned ($2.55) earnings per share. The company’s revenue was up 2356.5% on a year-over-year basis. On average, equities research analysts expect that Cytokinetics, Incorporated will post -5.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CYTK. UBS Group reiterated a “buy” rating and set a $104.00 price objective on shares of Cytokinetics in a research note on Wednesday, October 14th. Royal Bank Of Canada upped their target price on Cytokinetics from $112.00 to $113.00 and gave the company an “outperform” rating in a research report on Thursday, October 8th. HC Wainwright reiterated a “buy” rating and set a $140.00 target price on shares of Cytokinetics in a research note on Monday, October 19th. Citigroup lifted their price target on Cytokinetics from $99.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Finally, Truist Financial boosted their price target on Cytokinetics from $106.00 to $112.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Nineteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $106.50.

Check Out Our Latest Stock Analysis on Cytokinetics

Hedge Funds Weigh In On Cytokinetics

A number of hedge funds have recently bought and sold shares of the business. Siren L.L.C. acquired a new stake in Cytokinetics during the first quarter worth approximately $40,466,000. Jump Financial LLC bought a new position in Cytokinetics during the 3rd quarter worth $14,556,000. Hsbc Holdings PLC increased its stake in Cytokinetics by 5,906.5% during the 1st quarter. Hsbc Holdings PLC now owns 221,999 shares of the biopharmaceutical company’s stock worth $14,632,000 after acquiring an additional 218,303 shares during the period. Aberdeen Group plc increased its stake in Cytokinetics by 182.8% during the 3rd quarter. Aberdeen Group plc now owns 337,728 shares of the biopharmaceutical company’s stock worth $22,260,000 after acquiring an additional 218,293 shares during the period. Finally, Pictet Asset Management Holding SA raised its holdings in Cytokinetics by 18.4% in the 3rd quarter. Pictet Asset Management Holding SA now owns 1,374,523 shares of the biopharmaceutical company’s stock valued at $90,569,000 after acquiring an additional 214,060 shares in the last quarter.

About Cytokinetics

(Get Free Report)

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.

Featured Articles

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.